9 Meters Biopharma Debt to Equity

9 Meters Biopharma's debt-to-equity ratio stands at -0.82. That is below the Technology sector average of 0.4. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

9 Meters Biopharma sits lower the Technology benchmark (0.4) with a debt-to-equity ratio of -0.82. That is roughly 305.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether -0.82 is attractive depends on 9 Meters Biopharma's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how 9 Meters Biopharma's debt-to-equity ratio evolved across reporting periods, while the comparison chart places NMTR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Technology, debt-to-equity ratio is commonly used to spot outliers. 9 Meters Biopharma's reading of -0.82 (sector avg 0.4) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.